RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ) RSLBF Peers
See (RSLBF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RSLBF | $32.19 | N/A | 1.1B | 47.33 | $0.68 | +0.98% |
| PMCUF | $176.00 | N/A | 18.4B | 283.87 | $0.62 | +0.11% |
| MTHRY | $7.49 | -0.13% | 10.2B | 35.67 | $0.21 | N/A |
| MTHRF | $12.95 | N/A | 8.8B | 31.59 | $0.41 | +0.01% |
| PANHF | $0.88 | N/A | 1.9B | 88.20 | $0.01 | +141.33% |
| CMPUY | $24.80 | N/A | 1.3B | 42.03 | $0.59 | N/A |
| PIAHY | $2.29 | N/A | 1.2B | 114.50 | $0.02 | +217.08% |
| CMPVF | $23.85 | N/A | 1.2B | 41.13 | $0.58 | +5.46% |
| CRWRF | $27.32 | N/A | 956.7M | 63.53 | $0.43 | +1.38% |
| SUSRF | $15.43 | +2.99% | 787.3M | 53.21 | $0.29 | N/A |
Stock Comparison
RSLBF vs PMCUF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, PMCUF has a market cap of 18.4B. Regarding current trading prices, RSLBF is priced at $32.19, while PMCUF trades at $176.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas PMCUF's P/E ratio is 283.87. In terms of profitability, RSLBF's ROE is +0.26%, compared to PMCUF's ROE of +0.48%. Regarding short-term risk, RSLBF is more volatile compared to PMCUF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MTHRY Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MTHRY has a market cap of 10.2B. Regarding current trading prices, RSLBF is priced at $32.19, while MTHRY trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MTHRY's P/E ratio is 35.67. In terms of profitability, RSLBF's ROE is +0.26%, compared to MTHRY's ROE of +0.09%. Regarding short-term risk, RSLBF is more volatile compared to MTHRY. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MTHRF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MTHRF has a market cap of 8.8B. Regarding current trading prices, RSLBF is priced at $32.19, while MTHRF trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MTHRF's P/E ratio is 31.59. In terms of profitability, RSLBF's ROE is +0.26%, compared to MTHRF's ROE of +0.09%. Regarding short-term risk, RSLBF is more volatile compared to MTHRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs PANHF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, PANHF has a market cap of 1.9B. Regarding current trading prices, RSLBF is priced at $32.19, while PANHF trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas PANHF's P/E ratio is 88.20. In terms of profitability, RSLBF's ROE is +0.26%, compared to PANHF's ROE of -0.00%. Regarding short-term risk, RSLBF is more volatile compared to PANHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CMPUY Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CMPUY has a market cap of 1.3B. Regarding current trading prices, RSLBF is priced at $32.19, while CMPUY trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CMPUY's P/E ratio is 42.03. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMPUY's ROE of +0.04%. Regarding short-term risk, RSLBF is more volatile compared to CMPUY. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs PIAHY Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, PIAHY has a market cap of 1.2B. Regarding current trading prices, RSLBF is priced at $32.19, while PIAHY trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas PIAHY's P/E ratio is 114.50. In terms of profitability, RSLBF's ROE is +0.26%, compared to PIAHY's ROE of -0.00%. Regarding short-term risk, RSLBF is more volatile compared to PIAHY. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CMPVF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CMPVF has a market cap of 1.2B. Regarding current trading prices, RSLBF is priced at $32.19, while CMPVF trades at $23.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CMPVF's P/E ratio is 41.13. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMPVF's ROE of +0.04%. Regarding short-term risk, RSLBF is more volatile compared to CMPVF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CRWRF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CRWRF has a market cap of 956.7M. Regarding current trading prices, RSLBF is priced at $32.19, while CRWRF trades at $27.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CRWRF's P/E ratio is 63.53. In terms of profitability, RSLBF's ROE is +0.26%, compared to CRWRF's ROE of +0.04%. Regarding short-term risk, RSLBF is more volatile compared to CRWRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs SUSRF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, SUSRF has a market cap of 787.3M. Regarding current trading prices, RSLBF is priced at $32.19, while SUSRF trades at $15.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas SUSRF's P/E ratio is 53.21. In terms of profitability, RSLBF's ROE is +0.26%, compared to SUSRF's ROE of +0.03%. Regarding short-term risk, RSLBF is more volatile compared to SUSRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs SMSZF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, SMSZF has a market cap of 727.3M. Regarding current trading prices, RSLBF is priced at $32.19, while SMSZF trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas SMSZF's P/E ratio is 17.12. In terms of profitability, RSLBF's ROE is +0.26%, compared to SMSZF's ROE of +0.20%. Regarding short-term risk, RSLBF is more volatile compared to SMSZF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs RQHTF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, RQHTF has a market cap of 607.8M. Regarding current trading prices, RSLBF is priced at $32.19, while RQHTF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas RQHTF's P/E ratio is -0.20. In terms of profitability, RSLBF's ROE is +0.26%, compared to RQHTF's ROE of -2.22%. Regarding short-term risk, RSLBF is more volatile compared to RQHTF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs KSIOF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, KSIOF has a market cap of 449.5M. Regarding current trading prices, RSLBF is priced at $32.19, while KSIOF trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas KSIOF's P/E ratio is -238.10. In terms of profitability, RSLBF's ROE is +0.26%, compared to KSIOF's ROE of -0.05%. Regarding short-term risk, RSLBF is more volatile compared to KSIOF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs VHIBF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, VHIBF has a market cap of 416.8M. Regarding current trading prices, RSLBF is priced at $32.19, while VHIBF trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas VHIBF's P/E ratio is 257.33. In terms of profitability, RSLBF's ROE is +0.26%, compared to VHIBF's ROE of +0.02%. Regarding short-term risk, RSLBF is more volatile compared to VHIBF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs SMDCF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, SMDCF has a market cap of 280.9M. Regarding current trading prices, RSLBF is priced at $32.19, while SMDCF trades at $17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas SMDCF's P/E ratio is -17.32. In terms of profitability, RSLBF's ROE is +0.26%, compared to SMDCF's ROE of N/A. Regarding short-term risk, RSLBF is more volatile compared to SMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs DLHTF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, DLHTF has a market cap of 254.8M. Regarding current trading prices, RSLBF is priced at $32.19, while DLHTF trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas DLHTF's P/E ratio is -17.24. In terms of profitability, RSLBF's ROE is +0.26%, compared to DLHTF's ROE of -0.24%. Regarding short-term risk, RSLBF is more volatile compared to DLHTF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs VPAHF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, VPAHF has a market cap of 188.2M. Regarding current trading prices, RSLBF is priced at $32.19, while VPAHF trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas VPAHF's P/E ratio is -37.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to VPAHF's ROE of -0.18%. Regarding short-term risk, RSLBF is more volatile compared to VPAHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs COGZF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, COGZF has a market cap of 145.1M. Regarding current trading prices, RSLBF is priced at $32.19, while COGZF trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas COGZF's P/E ratio is 21.50. In terms of profitability, RSLBF's ROE is +0.26%, compared to COGZF's ROE of +0.17%. Regarding short-term risk, RSLBF is more volatile compared to COGZF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ACMLF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ACMLF has a market cap of 130.7M. Regarding current trading prices, RSLBF is priced at $32.19, while ACMLF trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ACMLF's P/E ratio is 30.33. In terms of profitability, RSLBF's ROE is +0.26%, compared to ACMLF's ROE of +0.21%. Regarding short-term risk, RSLBF is less volatile compared to ACMLF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ONVVF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ONVVF has a market cap of 129.8M. Regarding current trading prices, RSLBF is priced at $32.19, while ONVVF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ONVVF's P/E ratio is -8.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to ONVVF's ROE of -0.97%. Regarding short-term risk, RSLBF is more volatile compared to ONVVF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CSAMF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CSAMF has a market cap of 98.8M. Regarding current trading prices, RSLBF is priced at $32.19, while CSAMF trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CSAMF's P/E ratio is -9.64. In terms of profitability, RSLBF's ROE is +0.26%, compared to CSAMF's ROE of -1.58%. Regarding short-term risk, RSLBF is more volatile compared to CSAMF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MDPEF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MDPEF has a market cap of 61.3M. Regarding current trading prices, RSLBF is priced at $32.19, while MDPEF trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MDPEF's P/E ratio is 6.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDPEF's ROE of N/A. Regarding short-term risk, RSLBF is less volatile compared to MDPEF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs HITC Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, HITC has a market cap of 52.8M. Regarding current trading prices, RSLBF is priced at $32.19, while HITC trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas HITC's P/E ratio is -14.75. In terms of profitability, RSLBF's ROE is +0.26%, compared to HITC's ROE of -1.29%. Regarding short-term risk, RSLBF is more volatile compared to HITC. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs VASO Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, VASO has a market cap of 23.1M. Regarding current trading prices, RSLBF is priced at $32.19, while VASO trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas VASO's P/E ratio is 13.12. In terms of profitability, RSLBF's ROE is +0.26%, compared to VASO's ROE of +0.04%. Regarding short-term risk, RSLBF is more volatile compared to VASO. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs RTNXF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, RTNXF has a market cap of 22.5M. Regarding current trading prices, RSLBF is priced at $32.19, while RTNXF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas RTNXF's P/E ratio is -0.33. In terms of profitability, RSLBF's ROE is +0.26%, compared to RTNXF's ROE of +2.93%. Regarding short-term risk, RSLBF is less volatile compared to RTNXF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs HDSLF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, HDSLF has a market cap of 21.1M. Regarding current trading prices, RSLBF is priced at $32.19, while HDSLF trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas HDSLF's P/E ratio is -3.22. In terms of profitability, RSLBF's ROE is +0.26%, compared to HDSLF's ROE of -1.31%. Regarding short-term risk, RSLBF is more volatile compared to HDSLF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs THKKF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, THKKF has a market cap of 17.8M. Regarding current trading prices, RSLBF is priced at $32.19, while THKKF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas THKKF's P/E ratio is -1.51. In terms of profitability, RSLBF's ROE is +0.26%, compared to THKKF's ROE of -0.61%. Regarding short-term risk, RSLBF is more volatile compared to THKKF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs DGNOF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, DGNOF has a market cap of 15.5M. Regarding current trading prices, RSLBF is priced at $32.19, while DGNOF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas DGNOF's P/E ratio is -3.81. In terms of profitability, RSLBF's ROE is +0.26%, compared to DGNOF's ROE of +2.18%. Regarding short-term risk, RSLBF is more volatile compared to DGNOF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs TREIF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, TREIF has a market cap of 14.5M. Regarding current trading prices, RSLBF is priced at $32.19, while TREIF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas TREIF's P/E ratio is -2.08. In terms of profitability, RSLBF's ROE is +0.26%, compared to TREIF's ROE of -11.21%. Regarding short-term risk, RSLBF is more volatile compared to TREIF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs UDOCF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, UDOCF has a market cap of 14.4M. Regarding current trading prices, RSLBF is priced at $32.19, while UDOCF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas UDOCF's P/E ratio is -3.14. In terms of profitability, RSLBF's ROE is +0.26%, compared to UDOCF's ROE of +6.57%. Regarding short-term risk, RSLBF is more volatile compared to UDOCF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MNNDF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MNNDF has a market cap of 14.3M. Regarding current trading prices, RSLBF is priced at $32.19, while MNNDF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MNNDF's P/E ratio is -1.48. In terms of profitability, RSLBF's ROE is +0.26%, compared to MNNDF's ROE of N/A. Regarding short-term risk, RSLBF is more volatile compared to MNNDF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs AIMLF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, AIMLF has a market cap of 11.6M. Regarding current trading prices, RSLBF is priced at $32.19, while AIMLF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas AIMLF's P/E ratio is -1.67. In terms of profitability, RSLBF's ROE is +0.26%, compared to AIMLF's ROE of -11.81%. Regarding short-term risk, RSLBF is more volatile compared to AIMLF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs PBSV Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, PBSV has a market cap of 11.5M. Regarding current trading prices, RSLBF is priced at $32.19, while PBSV trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas PBSV's P/E ratio is -25.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to PBSV's ROE of -0.00%. Regarding short-term risk, RSLBF is more volatile compared to PBSV. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CRVW Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CRVW has a market cap of 10.7M. Regarding current trading prices, RSLBF is priced at $32.19, while CRVW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CRVW's P/E ratio is -1.84. In terms of profitability, RSLBF's ROE is +0.26%, compared to CRVW's ROE of +0.16%. Regarding short-term risk, RSLBF is more volatile compared to CRVW. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs HSCHF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, HSCHF has a market cap of 9.5M. Regarding current trading prices, RSLBF is priced at $32.19, while HSCHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas HSCHF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to HSCHF's ROE of +0.00%. Regarding short-term risk, RSLBF is more volatile compared to HSCHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs VYND Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, VYND has a market cap of 9.2M. Regarding current trading prices, RSLBF is priced at $32.19, while VYND trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas VYND's P/E ratio is -49.99. In terms of profitability, RSLBF's ROE is +0.26%, compared to VYND's ROE of +0.48%. Regarding short-term risk, RSLBF is more volatile compared to VYND. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs HBCNF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, HBCNF has a market cap of 8.4M. Regarding current trading prices, RSLBF is priced at $32.19, while HBCNF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas HBCNF's P/E ratio is -0.59. In terms of profitability, RSLBF's ROE is +0.26%, compared to HBCNF's ROE of -0.57%. Regarding short-term risk, RSLBF is more volatile compared to HBCNF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs SPLTF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, SPLTF has a market cap of 8M. Regarding current trading prices, RSLBF is priced at $32.19, while SPLTF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas SPLTF's P/E ratio is -2.60. In terms of profitability, RSLBF's ROE is +0.26%, compared to SPLTF's ROE of -6.63%. Regarding short-term risk, RSLBF is more volatile compared to SPLTF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CRBKF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CRBKF has a market cap of 6.8M. Regarding current trading prices, RSLBF is priced at $32.19, while CRBKF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CRBKF's P/E ratio is -1.40. In terms of profitability, RSLBF's ROE is +0.26%, compared to CRBKF's ROE of +68.80%. Regarding short-term risk, RSLBF is more volatile compared to CRBKF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs EMOR Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, EMOR has a market cap of 6.5M. Regarding current trading prices, RSLBF is priced at $32.19, while EMOR trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas EMOR's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EMOR's ROE of +0.28%. Regarding short-term risk, RSLBF is more volatile compared to EMOR. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs DOCRF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, DOCRF has a market cap of 6.2M. Regarding current trading prices, RSLBF is priced at $32.19, while DOCRF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas DOCRF's P/E ratio is -0.11. In terms of profitability, RSLBF's ROE is +0.26%, compared to DOCRF's ROE of -2.21%. Regarding short-term risk, RSLBF is more volatile compared to DOCRF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CMPD Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CMPD has a market cap of 5.4M. Regarding current trading prices, RSLBF is priced at $32.19, while CMPD trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CMPD's P/E ratio is -16.54. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMPD's ROE of +0.07%. Regarding short-term risk, RSLBF is more volatile compared to CMPD. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CNONF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CNONF has a market cap of 5M. Regarding current trading prices, RSLBF is priced at $32.19, while CNONF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CNONF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to CNONF's ROE of +1.60%. Regarding short-term risk, RSLBF is less volatile compared to CNONF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs RYAHF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, RYAHF has a market cap of 5M. Regarding current trading prices, RSLBF is priced at $32.19, while RYAHF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas RYAHF's P/E ratio is 0.25. In terms of profitability, RSLBF's ROE is +0.26%, compared to RYAHF's ROE of +0.00%. Regarding short-term risk, RSLBF is more volatile compared to RYAHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CDXFF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CDXFF has a market cap of 4.9M. Regarding current trading prices, RSLBF is priced at $32.19, while CDXFF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CDXFF's P/E ratio is -1.20. In terms of profitability, RSLBF's ROE is +0.26%, compared to CDXFF's ROE of +0.44%. Regarding short-term risk, RSLBF is more volatile compared to CDXFF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs IQAIF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, IQAIF has a market cap of 4.2M. Regarding current trading prices, RSLBF is priced at $32.19, while IQAIF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas IQAIF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to IQAIF's ROE of -1.62%. Regarding short-term risk, RSLBF is more volatile compared to IQAIF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MDBIF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MDBIF has a market cap of 4M. Regarding current trading prices, RSLBF is priced at $32.19, while MDBIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MDBIF's P/E ratio is -0.21. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDBIF's ROE of -0.14%. Regarding short-term risk, RSLBF is less volatile compared to MDBIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MITI Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MITI has a market cap of 3.9M. Regarding current trading prices, RSLBF is priced at $32.19, while MITI trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MITI's P/E ratio is -11.63. In terms of profitability, RSLBF's ROE is +0.26%, compared to MITI's ROE of -0.05%. Regarding short-term risk, RSLBF is more volatile compared to MITI. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CBDS Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CBDS has a market cap of 3.9M. Regarding current trading prices, RSLBF is priced at $32.19, while CBDS trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CBDS's P/E ratio is -1.35. In terms of profitability, RSLBF's ROE is +0.26%, compared to CBDS's ROE of +1.55%. Regarding short-term risk, RSLBF is more volatile compared to CBDS. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs TSTTF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, TSTTF has a market cap of 3.2M. Regarding current trading prices, RSLBF is priced at $32.19, while TSTTF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas TSTTF's P/E ratio is -1.25. In terms of profitability, RSLBF's ROE is +0.26%, compared to TSTTF's ROE of +0.33%. Regarding short-term risk, RSLBF is more volatile compared to TSTTF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CMHSF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CMHSF has a market cap of 2.2M. Regarding current trading prices, RSLBF is priced at $32.19, while CMHSF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CMHSF's P/E ratio is 1.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMHSF's ROE of +0.10%. Regarding short-term risk, RSLBF is less volatile compared to CMHSF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs EBYH Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, EBYH has a market cap of 2.1M. Regarding current trading prices, RSLBF is priced at $32.19, while EBYH trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas EBYH's P/E ratio is -6.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to EBYH's ROE of -0.03%. Regarding short-term risk, RSLBF is more volatile compared to EBYH. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs EKGGF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, EKGGF has a market cap of 2M. Regarding current trading prices, RSLBF is priced at $32.19, while EKGGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas EKGGF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EKGGF's ROE of +0.54%. Regarding short-term risk, RSLBF is less volatile compared to EKGGF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs BNVIF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, BNVIF has a market cap of 1.7M. Regarding current trading prices, RSLBF is priced at $32.19, while BNVIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas BNVIF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to BNVIF's ROE of -4.34%. Regarding short-term risk, RSLBF is less volatile compared to BNVIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs LVCE Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, LVCE has a market cap of 1.4M. Regarding current trading prices, RSLBF is priced at $32.19, while LVCE trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas LVCE's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to LVCE's ROE of N/A. Regarding short-term risk, RSLBF is more volatile compared to LVCE. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CTVEF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CTVEF has a market cap of 1.2M. Regarding current trading prices, RSLBF is priced at $32.19, while CTVEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CTVEF's P/E ratio is -0.23. In terms of profitability, RSLBF's ROE is +0.26%, compared to CTVEF's ROE of +0.08%. Regarding short-term risk, RSLBF is more volatile compared to CTVEF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CSOC Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CSOC has a market cap of 1.2M. Regarding current trading prices, RSLBF is priced at $32.19, while CSOC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CSOC's P/E ratio is 0.22. In terms of profitability, RSLBF's ROE is +0.26%, compared to CSOC's ROE of -2.38%. Regarding short-term risk, RSLBF is more volatile compared to CSOC. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs PPJE Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, PPJE has a market cap of 920.5K. Regarding current trading prices, RSLBF is priced at $32.19, while PPJE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas PPJE's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to PPJE's ROE of +0.00%. Regarding short-term risk, RSLBF is more volatile compared to PPJE. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MDXL Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MDXL has a market cap of 799K. Regarding current trading prices, RSLBF is priced at $32.19, while MDXL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MDXL's P/E ratio is -0.10. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDXL's ROE of +0.90%. Regarding short-term risk, RSLBF is more volatile compared to MDXL. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MDRM Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MDRM has a market cap of 765.3K. Regarding current trading prices, RSLBF is priced at $32.19, while MDRM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MDRM's P/E ratio is -0.60. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDRM's ROE of +0.42%. Regarding short-term risk, RSLBF is more volatile compared to MDRM. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs CGNSF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, CGNSF has a market cap of 664.1K. Regarding current trading prices, RSLBF is priced at $32.19, while CGNSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas CGNSF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to CGNSF's ROE of +0.96%. Regarding short-term risk, RSLBF is less volatile compared to CGNSF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs NEWUF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, NEWUF has a market cap of 633.4K. Regarding current trading prices, RSLBF is priced at $32.19, while NEWUF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas NEWUF's P/E ratio is -0.03. In terms of profitability, RSLBF's ROE is +0.26%, compared to NEWUF's ROE of +0.67%. Regarding short-term risk, RSLBF is more volatile compared to NEWUF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ACHKF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ACHKF has a market cap of 522.6K. Regarding current trading prices, RSLBF is priced at $32.19, while ACHKF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ACHKF's P/E ratio is -0.07. In terms of profitability, RSLBF's ROE is +0.26%, compared to ACHKF's ROE of +2.16%. Regarding short-term risk, RSLBF is less volatile compared to ACHKF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MDNWF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MDNWF has a market cap of 517.3K. Regarding current trading prices, RSLBF is priced at $32.19, while MDNWF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MDNWF's P/E ratio is -0.02. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDNWF's ROE of -1.53%. Regarding short-term risk, RSLBF is less volatile compared to MDNWF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs NDATF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, NDATF has a market cap of 450.5K. Regarding current trading prices, RSLBF is priced at $32.19, while NDATF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas NDATF's P/E ratio is -0.55. In terms of profitability, RSLBF's ROE is +0.26%, compared to NDATF's ROE of -0.62%. Regarding short-term risk, RSLBF is more volatile compared to NDATF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs DTRK Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, DTRK has a market cap of 370.6K. Regarding current trading prices, RSLBF is priced at $32.19, while DTRK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas DTRK's P/E ratio is -4.83. In terms of profitability, RSLBF's ROE is +0.26%, compared to DTRK's ROE of -9.79%. Regarding short-term risk, RSLBF is more volatile compared to DTRK. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs EVAHF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, EVAHF has a market cap of 327.7K. Regarding current trading prices, RSLBF is priced at $32.19, while EVAHF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas EVAHF's P/E ratio is -2.60. In terms of profitability, RSLBF's ROE is +0.26%, compared to EVAHF's ROE of +0.29%. Regarding short-term risk, RSLBF is more volatile compared to EVAHF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs LFCOF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, LFCOF has a market cap of 282K. Regarding current trading prices, RSLBF is priced at $32.19, while LFCOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas LFCOF's P/E ratio is -0.04. In terms of profitability, RSLBF's ROE is +0.26%, compared to LFCOF's ROE of +8.70%. Regarding short-term risk, RSLBF is less volatile compared to LFCOF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs EWLL Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, EWLL has a market cap of 185.1K. Regarding current trading prices, RSLBF is priced at $32.19, while EWLL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas EWLL's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EWLL's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to EWLL. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ALDNF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ALDNF has a market cap of 160.4K. Regarding current trading prices, RSLBF is priced at $32.19, while ALDNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ALDNF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to ALDNF's ROE of +0.00%. Regarding short-term risk, RSLBF is more volatile compared to ALDNF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs USPS Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, USPS has a market cap of 158.5K. Regarding current trading prices, RSLBF is priced at $32.19, while USPS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas USPS's P/E ratio is -1.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to USPS's ROE of -0.63%. Regarding short-term risk, RSLBF is more volatile compared to USPS. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs EMYSF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, EMYSF has a market cap of 151.7K. Regarding current trading prices, RSLBF is priced at $32.19, while EMYSF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas EMYSF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EMYSF's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to EMYSF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs NMXS Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, NMXS has a market cap of 116.8K. Regarding current trading prices, RSLBF is priced at $32.19, while NMXS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas NMXS's P/E ratio is -0.31. In terms of profitability, RSLBF's ROE is +0.26%, compared to NMXS's ROE of +1.59%. Regarding short-term risk, RSLBF is more volatile compared to NMXS. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs DSOL Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, DSOL has a market cap of 88.9K. Regarding current trading prices, RSLBF is priced at $32.19, while DSOL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas DSOL's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to DSOL's ROE of +0.05%. Regarding short-term risk, RSLBF is more volatile compared to DSOL. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs PASO Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, PASO has a market cap of 74.1K. Regarding current trading prices, RSLBF is priced at $32.19, while PASO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas PASO's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to PASO's ROE of +6.20%. Regarding short-term risk, RSLBF is more volatile compared to PASO. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ICCO Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ICCO has a market cap of 71.7K. Regarding current trading prices, RSLBF is priced at $32.19, while ICCO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ICCO's P/E ratio is -0.40. In terms of profitability, RSLBF's ROE is +0.26%, compared to ICCO's ROE of +0.17%. Regarding short-term risk, RSLBF is less volatile compared to ICCO. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs REFG Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, REFG has a market cap of 60.8K. Regarding current trading prices, RSLBF is priced at $32.19, while REFG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas REFG's P/E ratio is -0.01. In terms of profitability, RSLBF's ROE is +0.26%, compared to REFG's ROE of +0.01%. Regarding short-term risk, RSLBF is more volatile compared to REFG. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs SOFE Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, SOFE has a market cap of 45.1K. Regarding current trading prices, RSLBF is priced at $32.19, while SOFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas SOFE's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to SOFE's ROE of +0.52%. Regarding short-term risk, RSLBF is less volatile compared to SOFE. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs HDVY Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, HDVY has a market cap of 41.2K. Regarding current trading prices, RSLBF is priced at $32.19, while HDVY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas HDVY's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to HDVY's ROE of +0.00%. Regarding short-term risk, RSLBF is more volatile compared to HDVY. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs IGRW Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, IGRW has a market cap of 39.8K. Regarding current trading prices, RSLBF is priced at $32.19, while IGRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas IGRW's P/E ratio is -0.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to IGRW's ROE of +7.88%. Regarding short-term risk, RSLBF is less volatile compared to IGRW. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs WMGR Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, WMGR has a market cap of 36.3K. Regarding current trading prices, RSLBF is priced at $32.19, while WMGR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas WMGR's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to WMGR's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to WMGR. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs SSYNF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, SSYNF has a market cap of 33.3K. Regarding current trading prices, RSLBF is priced at $32.19, while SSYNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas SSYNF's P/E ratio is -0.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to SSYNF's ROE of N/A. Regarding short-term risk, RSLBF is more volatile compared to SSYNF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs RVRC Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, RVRC has a market cap of 31.4K. Regarding current trading prices, RSLBF is priced at $32.19, while RVRC trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas RVRC's P/E ratio is -0.09. In terms of profitability, RSLBF's ROE is +0.26%, compared to RVRC's ROE of -0.29%. Regarding short-term risk, RSLBF is less volatile compared to RVRC. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs TTBLF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, TTBLF has a market cap of 26.7K. Regarding current trading prices, RSLBF is priced at $32.19, while TTBLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas TTBLF's P/E ratio is -0.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to TTBLF's ROE of -1.03%. Regarding short-term risk, RSLBF is less volatile compared to TTBLF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ORHB Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ORHB has a market cap of 25.6K. Regarding current trading prices, RSLBF is priced at $32.19, while ORHB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ORHB's P/E ratio is -0.01. In terms of profitability, RSLBF's ROE is +0.26%, compared to ORHB's ROE of +0.33%. Regarding short-term risk, RSLBF is more volatile compared to ORHB. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs NHEL Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, NHEL has a market cap of 16.2K. Regarding current trading prices, RSLBF is priced at $32.19, while NHEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas NHEL's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to NHEL's ROE of +0.00%. Regarding short-term risk, RSLBF is more volatile compared to NHEL. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs FDBH Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, FDBH has a market cap of 15K. Regarding current trading prices, RSLBF is priced at $32.19, while FDBH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas FDBH's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to FDBH's ROE of +0.32%. Regarding short-term risk, RSLBF is more volatile compared to FDBH. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs HLTT Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, HLTT has a market cap of 10.7K. Regarding current trading prices, RSLBF is priced at $32.19, while HLTT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas HLTT's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to HLTT's ROE of +1789941.38%. Regarding short-term risk, RSLBF is more volatile compared to HLTT. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs MOSTQ Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, MOSTQ has a market cap of 8.5K. Regarding current trading prices, RSLBF is priced at $32.19, while MOSTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas MOSTQ's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to MOSTQ's ROE of +2.26%. Regarding short-term risk, RSLBF is more volatile compared to MOSTQ. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ACNV Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ACNV has a market cap of 8.1K. Regarding current trading prices, RSLBF is priced at $32.19, while ACNV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ACNV's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to ACNV's ROE of +0.00%. Regarding short-term risk, RSLBF is more volatile compared to ACNV. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs AHGIF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, AHGIF has a market cap of 7.8K. Regarding current trading prices, RSLBF is priced at $32.19, while AHGIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas AHGIF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to AHGIF's ROE of -2.79%. Regarding short-term risk, RSLBF is less volatile compared to AHGIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs NHIQ Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, NHIQ has a market cap of 2.7K. Regarding current trading prices, RSLBF is priced at $32.19, while NHIQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas NHIQ's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to NHIQ's ROE of +0.35%. Regarding short-term risk, RSLBF is less volatile compared to NHIQ. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs BBLNF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, BBLNF has a market cap of 2.6K. Regarding current trading prices, RSLBF is priced at $32.19, while BBLNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas BBLNF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to BBLNF's ROE of +1.06%. Regarding short-term risk, RSLBF is more volatile compared to BBLNF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs PCYS Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, PCYS has a market cap of 1.1K. Regarding current trading prices, RSLBF is priced at $32.19, while PCYS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas PCYS's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to PCYS's ROE of -2.71%. Regarding short-term risk, RSLBF is less volatile compared to PCYS. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs OLMM Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, OLMM has a market cap of 1K. Regarding current trading prices, RSLBF is priced at $32.19, while OLMM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas OLMM's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to OLMM's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to OLMM. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs ETAOF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, ETAOF has a market cap of 512. Regarding current trading prices, RSLBF is priced at $32.19, while ETAOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas ETAOF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to ETAOF's ROE of -13.69%. Regarding short-term risk, RSLBF is less volatile compared to ETAOF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs LGBI Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, LGBI has a market cap of 50. Regarding current trading prices, RSLBF is priced at $32.19, while LGBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas LGBI's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to LGBI's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to LGBI. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs APYI Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, APYI has a market cap of 34. Regarding current trading prices, RSLBF is priced at $32.19, while APYI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas APYI's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to APYI's ROE of -0.60%. Regarding short-term risk, RSLBF is more volatile compared to APYI. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs VMCS Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, VMCS has a market cap of 0. Regarding current trading prices, RSLBF is priced at $32.19, while VMCS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas VMCS's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to VMCS's ROE of +3.10%. Regarding short-term risk, RSLBF is more volatile compared to VMCS. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.
RSLBF vs WTEQF Comparison
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.1B. In comparison, WTEQF has a market cap of 0. Regarding current trading prices, RSLBF is priced at $32.19, while WTEQF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 47.33, whereas WTEQF's P/E ratio is 1.78. In terms of profitability, RSLBF's ROE is +0.26%, compared to WTEQF's ROE of N/A. Regarding short-term risk, RSLBF is more volatile compared to WTEQF. This indicates potentially higher risk in terms of short-term price fluctuations for RSLBF.